You searched for "macular oedema"
Macular oedema after cataract surgery in diabetic patients
The authors describe a multi-centre prospective observational study of 293 participants that underwent cataract surgery who all had diabetic retinopathy without definite central-involved macular oedema. Forty-five clinical sites took part throughout the United States. Patients were eligible if there was...
Cystoid macular oedema following cataract surgery
This review covers the history, incidence, diagnosis, risk factors, pathophysiology and medical management of postoperative macular oedema (PCMO), with a particular emphasis on key contemporary studies and novel observations. The authors revisit the incidence of well-established risk factors including intraoperative...
Cystoid macular oedema following retinal detachment surgery
There are limited studies examining the incidence and risk factors for postoperative cystoid macular oedema (CMO) following rhegmatogenous retinal detachment (RRD) repair. Postoperative CMO is thought to be due to pro-inflammatory state, where numerous cytokines lead to tight junction dysfunction,...Management of diabetic macular oedema in vitrectomised eyes
Diabetic macular oedema (DMO) is one of the leading causes of blindness; its prevalence is on the rise with progressive increase in numbers of people suffering from diabetes. The management of DMO has evolved significantly over the past few years....
Bromfenac versus betamethasone in diabetic macular oedema
This is a randomised, prospective, single-centre trial in patients diagnosed with diabetic macular oedema (DMO) with central subfield thickness (CST) of 250-500µm, who refused anti-VEGF treatment. Nineteen eyes of 19 patients were randomised to bromfenac (BF) or betamethasone (BM) drops,...
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...
Steroid treatment for pseudophakic cystoid macular oedema
The authors present a retrospective comparison of 45 eyes of 41 patients treated with 2mg intravitreal triamcinolone (IVT group) and 50 eyes of 42 patients treated with 40mg sub-Tenons triamcinolone (STT group) for pseudophakic cystoid macular oedema (CMO). The visual...
Prophylaxis for clinical macular oedema after phacoemulsification
The authors report on a retrospective cohort study looking at three different prophylaxis methods for macular oedema after cataract surgery: 1) Topical prednisolone acetate (PA) alone; 2) Topical PA in combination with non-steroidal anti-inflammatory drug (NSAID); 3) Intraoperative subconjunctival injection...
Rebound phenomenon after IVT triamcinolone acetonide for macular oedema
In this retrospective study, the authors report the rebound phenomenon after intravitreal triamcinolone acetonide (IVTA) injection for macular oedema secondary to diabetic retinopathy (DR) and central (CRVO) or branch retinal vein occlusion (BRVO). The incidence of a rebound phenomenon was...
OCT biomarkers in asymmetric anti-VEGF response in bilateral diabetic macular oedema
This study aimed to identify optical coherence tomography (OCT) biomarkers for predicting response to anti-VEGF treatment in diabetic macular oedema (DMO). Bilateral DMO patients with asymmetric response to a loading dose of anti-VEGF (ranibizumab / aflibercept) treatment were retrospectively studied....Pathophysiology of diabetic macular oedema: why combination therapy may be better
The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...
